Literature DB >> 2387678

Bacteriochlorin a, a new photosensitizer in photodynamic therapy. In vivo results.

J J Schuitmaker1, J A van Best, J L van Delft, T M Dubbelman, J A Oosterhuis, D de Wolff-Rouendaal.   

Abstract

The photosensitizing properties of bacteriochlorin a (BCA), a nontoxic derivative of bacteriochlorophyll a, were investigated in vivo. BCA has an absorption band at a wavelength at which tissue penetration is optimal (760 nm), and it shows preferential tumor retention in Greene melanoma implanted in the anterior chamber of rabbit eyes. A dose of 20 mg/kg BCA was administered IV at 4-7 mm tumor diameter; 24 hr later the tumor was irradiated with near-infrared light (30 min, 760 nm, 150-280 J/cm2). On the day after the irradiation it appeared that tumor growth had stopped: fluorescein angiography showed nonperfusion of the tumor. Histopathology after enucleation showed subtotal tumor necrosis with occasionally small clusters of viable cells around a blood vessel and at the tumor periphery. Neither BCA nor light alone had any effect on the eye or melanoma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2387678

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  9 in total

Review 1.  Ophthalmic light sensitive nanocarrier systems.

Authors:  Jennifer G Christie; Uday B Kompella
Journal:  Drug Discov Today       Date:  2008-02-01       Impact factor: 7.851

2.  Stable synthetic cationic bacteriochlorins as selective antimicrobial photosensitizers.

Authors:  Liyi Huang; Ying-Ying Huang; Pawel Mroz; George P Tegos; Timur Zhiyentayev; Sulbha K Sharma; Zongshun Lu; Thiagarajan Balasubramanian; Michael Krayer; Christian Ruzié; Eunkyung Yang; Hooi Ling Kee; Christine Kirmaier; James R Diers; David F Bocian; Dewey Holten; Jonathan S Lindsey; Michael R Hamblin
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

Review 3.  Melanoma resistance to photodynamic therapy: new insights.

Authors:  Ying-Ying Huang; Daniela Vecchio; Pinar Avci; Rui Yin; Maria Garcia-Diaz; Michael R Hamblin
Journal:  Biol Chem       Date:  2013-02       Impact factor: 3.915

4.  Corneal neovascularization in rats as a model for photothrombotic therapy using bacteriochlorin a and an argon laser.

Authors:  C A van Gool; H J Schuitmaker; M J Jager
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-07       Impact factor: 3.117

5.  Higher irradiance and photodynamic therapy for age-related macular degeneration (an AOS thesis).

Authors:  Joan W Miller
Journal:  Trans Am Ophthalmol Soc       Date:  2008

Review 6.  Current status of photodynamic therapy in oncology.

Authors:  R van Hillegersberg; W J Kort; J H Wilson
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

7.  Interstitial photodynamic therapy with the second-generation photosensitizer bacteriochlorin a in a rat model for liver metastases.

Authors:  J P Rovers; J J Schuitmaker; A L Vahrmeijer; J H van Dierendonck; O T Terpstra
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

8.  Fluorescence and photodynamic effects of bacteriochlorin a observed in vivo in 'sandwich' observation chambers.

Authors:  H L van Leengoed; J J Schuitmaker; N van der Veen; T M Dubbelman; W M Star
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

9.  Mechanisms for optimising photodynamic therapy: second-generation photosensitisers in combination with mitomycin C.

Authors:  I P van Geel; H Oppelaar; Y G Oussoren; J J Schuitmaker; F A Stewart
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.